A phase II/III study of trans sodium crocetinate (TSC) in the treatment of pancreatic cancer.
Phase of Trial: Phase II
Latest Information Update: 28 Mar 2016
At a glance
- Drugs Transcrocetinate sodium (Primary)
- Indications Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- 28 Mar 2016 According to a Diffusion Pharmaceuticals media release, the company is planning to commence this trial in the first half of 2017.
- 14 Jan 2016 According to a Diffusion Pharmaceuticals media release, the company is planning to commence a phase II/III trial in pancreatic cancer in 2016.
- 14 Jan 2016 New trial record